ORGO News and Press, Organogenesis Holdings Inc. From 04/05/22

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the lates...

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, t...

The following slide deck was published by Organogenesis Holdings Inc. in conjunction with this event. For further details see: Organogenesis Holdings (ORGO) Investor Presentation - Slideshow

Picture this: You've just found a stock that looks like it's a massive bargain on the basis of its valuation ratios. In the recent year, the company has grown, and there's no obvious red flags when it comes to debt, profitability, or leadership. You buy the stock only to see it go down over...

CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, h...

Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...

CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, tod...

Wednesday wasn't a particularly tough Hump Day to surmount for regenerative medicine specialist Organogenesis Holdings (NASDAQ: ORGO) . The company's stock soared by over 21% thanks to a rather encouraging quarterly-earnings report delivered after market hours on Tuesday. For it...

Organogenesis (ORGO +22.4%) a regenerative medicine company based in Canton, Massachusetts, has recorded the biggest intra-day gain since January 2021 on Wednesday after reporting better than expected financials for Q4 2021 with a strong earnings beat. “We delivered strong fourth-quart...

Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...